

The Coalition for Epidemic Preparedness and Innovations: a global partnership

Frederik Kristensen MD, MBA, MPH
Deputy CEO, CEPI
October 30, 2018



DEPARTMENT OF BIOTECHNOLOGY
Ministry of Science & Technology

Overview

- About CEPI
- Our priorities and investments
- Further areas of collaboration




What is CEPI?

- Launch: Davos World Economic Forum 2017
- Global coalition of public, private, philanthropic and civil society organisations
- To stimulate, finance and coordinate vaccine development for emerging infectious diseases



- Identify priority threats and act when market forces fail to drive needed development
- Move vaccine candidates through late preclinical studies to proof of concept and safety in humans
- Build capabilities for rapid response to unknown threats

CEPI: vision, mission, strategic objectives




How CEPI works




CEPI's initial priority pathogens


MERS







Lassa



Nipah



Disease X



Just in case vaccine: MERS, Lassa, Nipah

- More than 30 proposals received in first call for proposals
- Applications from:
 - Academic institutions, biotechs, large pharmaceutical companies, and Product Development Partnerships
 - Broad diversity in vaccine platform technologies
 - Proposals from North America, Europe, Africa, Middle East, South East Asia and Australia
- Rigorous process of selection, involving:
 - An objective review of proposals by experts and our Scientific Advisory Committee
 - Rigorous budget challenge and negotiation of the agreements to meet CEPI's budget, governance, and equitable access requirement


Seven partnership agreements signed



Disease	Lassa and MERS	Lassa and MERS	Lassa	Nipah	Lassa	MERS	Lassa, MERS, and Nipah
Investment (up to)	\$37.5 M	\$56.0	\$54.9 M	\$25.0 M	\$36.0 M	\$36.0 M	\$19.0M

CEPI priority pathogen portfolio

CEPI funds late preclinical through phase II S&I and investigational stockpile generation



Just in time vaccines: platform technologies

CEPI supports development of vaccine platform technologies that can be rapidly deployed against known and newly emerging pathogens, to limit or prevent future outbreaks.

Projects must demonstrate:

- Safety and immunogenicity
- Validation of the platform using 3 pathogens
 - 2 with known correlates of protection & validated animal model;
 - 1 from the WHO priority pathogen list
- Manufacturing performance
 - 16 weeks for development of vaccine candidate for a new pathogen
 - 6 weeks to clinical benefit after 1st dose
 - 8 weeks to produce 100,000 doses after go-decision
- Funding decisions to be announced Q4, 2018

Sustainable manufacturing

- Task force to analyse and propose solutions for sustainable manufacturing of EID vaccines
- The solution will be fully integrated and address the end-to-end supply chain to make vaccines available to affected populations, at an affordable price, when needed
- Look at both manufacturing technologies and economic and structural attributes to sustain the solution over time
- DCVMN will have a role to play — Atin Tomar is DCVMN representative in the working group



www.cepi.net